Amicus Therapeutics, Inc.

As of October 10, 2025, Amicus Therapeutics, Inc. shows a mildly bullish trend with mixed signals from technical indicators, having returned 1.22% over the past week and 4.53% over the past month, but is down 11.89% year-to-date compared to the S&P 500's 11.41% gain.

As of October 10, 2025, Amicus Therapeutics, Inc. shows a mildly bullish trend with a 4.53% monthly return, but has underperformed year-to-date at -11.89% compared to the S&P 500's 11.41%, amid mixed technical signals.

As of August 1, 2025, Amicus Therapeutics, Inc. has a mildly bearish trend, with mixed technical indicators and underperformance against the S&P 500, showing a year-to-date return of -9.98% compared to the index's 12.22%.

As of November 7, 2016, Amicus Therapeutics, Inc. is considered risky and overvalued compared to its peers, with a high Price to Book Value of 9.80 and an EV to EBITDA ratio of 36.52, while its stock has underperformed over the year with a return of -9.98% compared to the S&P 500's 12.22%.

As of November 7, 2016, Amicus Therapeutics, Inc. is considered risky and overvalued due to high Price to Book and EV to EBITDA ratios, a negative ROE, and significant underperformance compared to the S&P 500.

As of February 19, 2025, Amicus Therapeutics, Inc. has a bearish technical outlook, indicated by negative MACD, moving averages, and KST across multiple time frames, along with underperformance compared to the S&P 500.

As of March 2022, the management team of Amicus Therapeutics, Inc. includes Chairman and CEO John Crowley, President and COO Bradley Campbell, and several independent directors: Michael Raab, Lynn Bleil, Robert Essner, Michael Kelly, and Margaret McGlynn.

Amicus Therapeutics, Inc. is a biotechnology company focused on developing treatments for rare metabolic diseases, with a market capitalization of approximately $1.79 billion. As of March 2025, it reported net sales of $125 million and a net loss of $22 million.

As of Jun 18, Amicus Therapeutics, Inc. has a market capitalization of $1.786 billion, with net sales of $543.15 million and a net profit of -$29.38 million over the latest four quarters. The company reported shareholder's funds of $194.04 million and total assets of $785.03 million as of Dec 24.